The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.

BACKGROUND: Evidence suggests that an early interventional strategy for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) can improve health outcomes but also increase costs when compared with a conservative strategy. OBJECTIVE: The aim of this study was to assess the cost-effectiven...

Descripción completa

Detalles Bibliográficos
Publicado en:Heart Vol. 94; no. 6; pp. 717 - 724
Autores principales: Henriksson M, Epstein DM, Palmer SJ, Sculpher MJ, Clayton TC, Pocock SJ, Henderson RA, Buxton MJ, Fox KA
Formato: research Journal Article
Publicado: BMJ Publishing Group Jun2008
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105747787&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105747787
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        13556037
        1XU
      jtl: Heart
      issn: 13556037
      maglogo: N
    pubinfo:
      dt: Jun2008
      vid: 94
      iid: 6
      pid: 8280
      pub: BMJ Publishing Group
    artinfo:
      ui:
        105747787
        2009939365
        10.1136/hrt.2007.127340
        NLM18032459
        105747787
      ppf: 717
      ppct: 7
      formats:
      tig:
        atl: The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
      aug:
        au:
          Henriksson M
          Epstein DM
          Palmer SJ
          Sculpher MJ
          Clayton TC
          Pocock SJ
          Henderson RA
          Buxton MJ
          Fox KA
        affil: Centre for Health Economics, University of York, UK. martin.henriksson@ihs.liu.se
      sug:
        subj:
          Coronary Angiography Economics
          Life Table Method
          Acute Coronary Syndrome Economics
          Aged
          Aged, 80 and Over
          Angina, Unstable Economics
          Angina, Unstable Therapy
          Clinical Trials
          Cost Benefit Analysis Economics
          Costs and Cost Analysis
          Cox Proportional Hazards Model
          Diabetic Angiopathies Therapy
          Female
          Male
          Middle Age
          Multicenter Studies
          Acute Coronary Syndrome Mortality
          Acute Coronary Syndrome Therapy
          Human
          Aged: 65+ years
          Aged, 80 & over
          Middle Aged: 45-64 years
          Female
          Male
      ab: BACKGROUND: Evidence suggests that an early interventional strategy for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) can improve health outcomes but also increase costs when compared with a conservative strategy. OBJECTIVE: The aim of this study was to assess the cost-effectiveness of an early interventional strategy in different risk groups from a UK health-service perspective. DESIGN: Decision-analytic model based on randomised clinical trial data. MAIN OUTCOME MEASURES: Costs in UK Sterling at 2003/2004 prices and quality-adjusted life years (QALYs) combined into an incremental cost-effectiveness ratio. METHODS: Data from the third Randomised Intervention Trial of unstable Angina (RITA 3) was employed to estimate rates of cardiovascular death and myocardial infarction, costs and health-related quality of life. Cost-effectiveness was estimated over patients' lifetimes within the decision-analytic model. RESULTS: The mean incremental cost per QALY gained for an early interventional strategy was approximately 55,000 pounds sterling, 22,000 pounds sterling and 12,000 pounds sterling for patients at low, intermediate and high risk, respectively. The early interventional strategy is approximately 1%, 35% and 95% likely to be cost-effective for patients at low, intermediate and high risk, respectively, at a threshold of 20,000 pounds sterling per QALY. The cost-effectiveness of early intervention in low-risk patients is sensitive to assumptions about the duration of the treatment effect. CONCLUSION: An early interventional strategy in patients presenting with NSTE-ACS is likely to be considered cost-effective for patients at high and intermediate risk, but this is less likely to be the case for patients at low risk.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N